Mr. Speaker, we have heard in the past that the patchwork quilt of programs available to people cover perhaps as many as 60% of Canadians. However, as has been pointed out, this leads to inefficiencies and higher prices. One concern that many would have is whether a move to a single-payer public system to cover the costs of pharmaceuticals would involve a shift of costs from private companies, which currently contribute through their individual plans, to the government.
In the House of Commons on March 12th, 2020. See this statement in context.